Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $70.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 36.37% from the stock’s current price.

A number of other brokerages have also issued reports on ETON. B. Riley Financial reaffirmed a “buy” rating and set a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group boosted their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $71.50.

Eton Pharmaceuticals Stock Performance

ETON stock traded down $1.55 on Wednesday, reaching $51.33. 462,258 shares of the company were exchanged, compared to its average volume of 450,186. Eton Pharmaceuticals has a 12 month low of $14.27 and a 12 month high of $66.37. The stock’s fifty day moving average price is $56.27 and its 200 day moving average price is $40.90. The firm has a market capitalization of $1.47 billion, a PE ratio of 135.08 and a beta of 0.90. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. On average, research analysts anticipate that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director owned 59,745 shares of the company’s stock, valued at $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the sale, the insider directly owned 43,381 shares in the company, valued at $2,388,991.67. This trade represents a 8.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,166 shares of company stock worth $4,809,672 in the last three months. Insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $68,629,000. Nantahala Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $42,569,426. Pillsbury Lake Capital LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $14,015,083. Panoramic Capital LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $7,537,000. Finally, Cannell Capital LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $6,181,041. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.